Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Our deep pipeline of fundamentally innovative clinical and preclinical anti-infective programs is designed to revolutionize the way physicians treat serious bacterial diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/04/16 | $50,000,000 | Series B |
AstraZeneca Clarus Ventures Eventide Asset Management Frazier Healthcare Novo A/S | undisclosed |
| 09/05/17 | $31,900,000 | Series B-1 |
Sofinnova Ventures TPG Biotech | undisclosed |
